These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 35526308)
1. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308 [TBL] [Abstract][Full Text] [Related]
2. RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab. Miao R; Kim DW; Yu J; Malafa M; Mehta R; Strosberg J; Imanirad I; Iyer S; Uhlik M; Benjamin L; Kim R Oncology; 2024; 102(7):549-555. PubMed ID: 38061339 [TBL] [Abstract][Full Text] [Related]
3. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640 [TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Kim DW; Tan E; Zhou JM; Schell MJ; Martinez M; Yu J; Carballido E; Mehta R; Strosberg J; Imanirad I; Kim RD Br J Cancer; 2021 May; 124(11):1803-1808. PubMed ID: 33828254 [TBL] [Abstract][Full Text] [Related]
5. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. Fakih M; Raghav KPS; Chang DZ; Larson T; Cohn AL; Huyck TK; Cosgrove D; Fiorillo JA; Tam R; D'Adamo D; Sharma N; Brennan BJ; Wang YA; Coppieters S; Zebger-Gong H; Weispfenning A; Seidel H; Ploeger BA; Mueller U; Oliveira CSV; Paulson AS EClinicalMedicine; 2023 Apr; 58():101917. PubMed ID: 37090438 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271 [TBL] [Abstract][Full Text] [Related]
7. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. Overman MJ; Gelsomino F; Aglietta M; Wong M; Limon Miron ML; Leonard G; García-Alfonso P; Hill AG; Cubillo Gracian A; Van Cutsem E; El-Rayes B; McCraith SM; He B; Lei M; Lonardi S J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821718 [TBL] [Abstract][Full Text] [Related]
9. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Clarke JM; Blobe GC; Strickler JH; Uronis HE; Zafar SY; Morse M; Dropkin E; Howard L; O'Neill M; Rushing CN; Niedzwiecki D; Watson H; Bolch E; Arrowood C; Liu Y; Nixon AB; Hurwitz HI Cancer Chemother Pharmacol; 2019 Oct; 84(4):909-917. PubMed ID: 31444620 [TBL] [Abstract][Full Text] [Related]
10. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541 [TBL] [Abstract][Full Text] [Related]
11. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336 [TBL] [Abstract][Full Text] [Related]
12. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F; Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555 [TBL] [Abstract][Full Text] [Related]
14. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. Hernando-Calvo A; Han M; Ayodele O; Wang BX; Bruce JP; Abbas-Aghababazadeh F; Vila-Casadesús M; Sanz-Garcia E; Yang SYC; Berman HK; Vivancos A; Lam B; Lungu I; Salawu A; Stayner LA; Haibe-Kains B; Bedard PL; Avery L; Razak ARA; Pugh TJ; Spreafico A; Siu LL; Hansen AR Clin Colorectal Cancer; 2024 Sep; 23(3):272-284.e9. PubMed ID: 38960798 [TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X Front Oncol; 2020; 10():594125. PubMed ID: 33282742 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study. Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379). Almhanna K; Breakstone R; Raufi A; Wood R; Webber A; Dionson S; Cavanagh L; Seyhan AA; Safran H; El-Deiry W Transl Gastroenterol Hepatol; 2024; 9():15. PubMed ID: 38716219 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. Jiang FE; Zhang HJ; Yu CY; Liu AN Neoplasma; 2021 Jul; 68(4):861-866. PubMed ID: 33998237 [TBL] [Abstract][Full Text] [Related]
19. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Kim DW; Kim YC; Kovari BP; Martinez M; Miao R; Yu J; Mehta R; Strosberg J; Imanirad I; Kim RD Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339307 [TBL] [Abstract][Full Text] [Related]
20. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]